1
|
Dellal F, Santo Domingo Porqueras D, Narayanin-Richenapin S, Thimotee M, Delahaye V, Diouf Y, Piasta K, Gumienna-Kontecka E, Kozlowski H, Beyler M, Tripier R, Moyeux A, Gager O, Besnard V, Salerno M. Multistep synthesis of a novel copper complex with potential for Alzheimer's disease diagnosis. J Biol Inorg Chem 2023; 28:777-790. [PMID: 37978078 DOI: 10.1007/s00775-023-02028-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2023] [Accepted: 09/12/2023] [Indexed: 11/19/2023]
Abstract
Positron emission tomography (PET) imaging of Aβ plaques, is recognized as a tool for the diagnosis of Alzheimer's disease. As a contribution to the development of new strategies for early diagnosis of the disease, using PET medical imaging technique, a new copper complex, the [Cu(TE1PA-ONO)]+ was synthesized in ten steps. The key step of our strategy is the coupling of a monopicolinate-N-alkylated cyclam-based ligand with a moiety capable of recognizing Aβ plaques via a successful and challenging Buchwald-Hartwig coupling reaction. To our knowledge, it is the first time that such a strategy is used to functionalize polyazamacrocyclic derivatives. The thermodynamic stability constants determined in MeOH/H2O solvent indicate that the attachment of this moiety does not weaken the chelating properties of TE1PA-ONO ligand in relation to parent HTE1PA. The novel complex described here is able to recognize amyloid plaques in brain sections from Alzheimer's disease patients and shows low toxicity to human neuronal cells.
Collapse
Affiliation(s)
- Fatma Dellal
- Université Sorbonne Paris Nord, UMR-CNRS 7244, Laboratoire Chimie, Structures, Propriétés de Biomatériaux et d'Agents Thérapeutiques (CSPBAT), équipe NBD, 1 rue de Chablis, 93000, Bobigny, France
| | - Diego Santo Domingo Porqueras
- Université Sorbonne Paris Nord, UMR-CNRS 7244, Laboratoire Chimie, Structures, Propriétés de Biomatériaux et d'Agents Thérapeutiques (CSPBAT), équipe NBD, 1 rue de Chablis, 93000, Bobigny, France
| | - Stacy Narayanin-Richenapin
- Université Sorbonne Paris Nord, UMR-CNRS 7244, Laboratoire Chimie, Structures, Propriétés de Biomatériaux et d'Agents Thérapeutiques (CSPBAT), équipe NBD, 1 rue de Chablis, 93000, Bobigny, France
| | - Marine Thimotee
- Université Sorbonne Paris Nord, UMR-CNRS 7244, Laboratoire Chimie, Structures, Propriétés de Biomatériaux et d'Agents Thérapeutiques (CSPBAT), équipe NBD, 1 rue de Chablis, 93000, Bobigny, France
| | - Vanessa Delahaye
- Université Sorbonne Paris Nord, UMR-CNRS 7244, Laboratoire Chimie, Structures, Propriétés de Biomatériaux et d'Agents Thérapeutiques (CSPBAT), équipe NBD, 1 rue de Chablis, 93000, Bobigny, France
| | - Yacine Diouf
- Université Sorbonne Paris Nord, UMR-CNRS 7244, Laboratoire Chimie, Structures, Propriétés de Biomatériaux et d'Agents Thérapeutiques (CSPBAT), équipe NBD, 1 rue de Chablis, 93000, Bobigny, France
| | - Karolina Piasta
- Faculty of Chemistry, University of Wroclaw, F. Joliot-Curie 14, 50-383, Wroclaw, Poland
| | | | - Henryk Kozlowski
- Department of Health Sciences, University of Opole, Katowicka 68, 45-060, Opole, Poland
| | - Maryline Beyler
- Univ Brest, UMR-CNRS 6521 CEMCA, UFR des Sciences et Techniques, 6 avenue Victor le Gorgeu, C.S. 93837, 29238, Brest, France
| | - Raphael Tripier
- Univ Brest, UMR-CNRS 6521 CEMCA, UFR des Sciences et Techniques, 6 avenue Victor le Gorgeu, C.S. 93837, 29238, Brest, France
| | - Alban Moyeux
- Université Sorbonne Paris Nord, UMR-CNRS 7244, Laboratoire Chimie, Structures, Propriétés de Biomatériaux et d'Agents Thérapeutiques (CSPBAT), équipe NBD, 1 rue de Chablis, 93000, Bobigny, France
| | - Olivier Gager
- Université Sorbonne Paris Nord, UMR-CNRS 7244, Laboratoire Chimie, Structures, Propriétés de Biomatériaux et d'Agents Thérapeutiques (CSPBAT), équipe NBD, 1 rue de Chablis, 93000, Bobigny, France
| | - Valérie Besnard
- Université Sorbonne Paris Nord, UMR1272, Laboratoire Hypoxie et Poumon, Plateforme TisCel 13, 1 rue de Chablis, 93000, Bobigny, France
| | - Milena Salerno
- Université Sorbonne Paris Nord, UMR-CNRS 7244, Laboratoire Chimie, Structures, Propriétés de Biomatériaux et d'Agents Thérapeutiques (CSPBAT), équipe NBD, 1 rue de Chablis, 93000, Bobigny, France.
| |
Collapse
|
2
|
Newberg AB, Coble R, Khosravi M, Alavi A. Positron Emission Tomography-Based Assessment of Cognitive Impairment and Dementias, Critical Role of Fluorodeoxyglucose in such Settings. PET Clin 2022; 17:479-494. [PMID: 35717103 DOI: 10.1016/j.cpet.2022.03.009] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Positron emission tomography (PET) has been a key component in the diagnostic armamentarium for assessing neurodegenerative diseases such as Alzheimer or Parkinson disease. PET imaging has been useful for diagnosing these disorders, identifying their pathophysiology, and following their treatment. Further, PET imaging has been extensively used for both clinical and research purposes, particularly for helping with potential therapeutic approaches for managing neurodegenerative diseases. This article will review the current literature regarding PET imaging in patients with neurodegenerative disorders. This includes an evaluation of the most commonly used tracer fluorodeoxyglucose that measures cerebral glucose metabolism, tracers that assess neurotransmitter systems, and tracers designed to reveal disease-specific pathophysiological processes. With the continuing development of an expanding variety of radiopharmaceuticals, PET imaging will likely play a prominent role in future research and clinical applications for neurodegenerative diseases.
Collapse
Affiliation(s)
- Andrew B Newberg
- Marcus Institute of Integrative Health, Thomas Jefferson University, 789 East Lancaster Avenue, Suite 110, Villanova, PA 19085, USA; Department of Radiology, Thomas Jefferson University, Philadelphia, PA, USA.
| | - Roger Coble
- Marcus Institute of Integrative Health, Thomas Jefferson University, 789 East Lancaster Avenue, Suite 110, Villanova, PA 19085, USA; University of California Berkeley, Berkeley, CA, USA
| | - Mohsen Khosravi
- Marcus Institute of Integrative Health, Thomas Jefferson University, 789 East Lancaster Avenue, Suite 110, Villanova, PA 19085, USA
| | - Abass Alavi
- Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA
| |
Collapse
|
3
|
Khosravi M, Peter J, Wintering NA, Serruya M, Shamchi SP, Werner TJ, Alavi A, Newberg AB. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer’s Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis. J Alzheimers Dis 2019; 70:1197-1207. [DOI: 10.3233/jad-190220] [Citation(s) in RCA: 36] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- Mohsen Khosravi
- Department of Radiology, Thomas Jefferson University, Philadelphia, PA, USA
| | - Jonah Peter
- Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA
| | - Nancy A. Wintering
- Marcus Institute of Integrative Health, Thomas Jefferson University, Philadelphia, PA, USA
| | - Mijail Serruya
- Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA
| | | | - Thomas J. Werner
- Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA
| | - Abass Alavi
- Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA
| | - Andrew B. Newberg
- Department of Radiology, Thomas Jefferson University, Philadelphia, PA, USA
- Marcus Institute of Integrative Health, Thomas Jefferson University, Philadelphia, PA, USA
| |
Collapse
|